Companies: 10,795·Total market cap: $144.5T

Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc

ADAPNASDAQHealthcare

$0.05

$-0.00(-3.00%)

Market Cap$75157679

P/E Ratio—

52W High$0.86

52W Low$0.0202

Avg Volume110.6M

Open$0.04

Beta2.49

Net Income Financials Revenue

Adaptimmune Therapeutics plc (ADAP) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ADAP · net income · updated Jun 8, 2026

Core profitability metrics

ADAP · net income · margin · TTM · CAGR

Net income was −$70.8M for FY2024 (fiscal year ending 2024-12-31), up 37.8% year-over-year. Net profit margin was -39.8%.

FY2024 Net Income−$70.8M▲ +37.8% YoY

Trailing 12M (TTM)−$169.8Mtrailing 4 quarters sum

Net Profit Margin-39.8%−$70.8M ÷ $178.0M

YoY Change+37.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · ADAP net income history · ADAP profit margin

Annual net income data

ADAP · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2024Loss−$70.8M▲ +37.8%-39.8%$178.0M

FY2023Loss−$113.9M▲ +31.2%-188.9%$60.3M

FY2022Loss−$165.5M▼ 4.7%-609.5%$27.1M

FY2021Loss−$158.1M▼ 21.5%-2571.0%$6.1M

FY2020Loss−$130.1M▲ +5.2%-3286.8%$4.0M

Net income vs peers (Healthcare)

ADAP vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Adaptimmune Therapeutics plcYOU

ADAP

−$70.8M+37.8%-39.8%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Adaptimmune Therapeutics plc (ADAP) reported net income of −$70.8M for FY2024 (fiscal year ending 2024-12-31), up 37.8% year-over-year. The net profit margin was -39.8% — meaning the company kept $-0.40 of every dollar of revenue as profit.

Adaptimmune Therapeutics plc has not yet achieved annual profitability based on available data (12 fiscal years). The company has reported net losses across all available periods.

Adaptimmune Therapeutics plc's net profit margin was -39.8% for FY2024, based on the latest annual results.

Investors sometimes search for "Adaptimmune Therapeutics plc net worth" — the company's market capitalization is a separate figure from ADAP net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ADAP net income · 4 questions

Adaptimmune Therapeutics plc is not currently profitable on an annual basis. The company reported a net loss of $70.8M for FY2024.

is ADAP profitabledoes ADAP make a profitADAP profitabilityADAP profitable company

▸ Source: FMP /income-statement · GAAP · Adaptimmune Therapeutics plc · Adaptimmune Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026